I hear you Gary, but they do have all the pieces except a top notch CEO.
Let's see who they come up with. I think there will be time right after they announce to perform DD on who ever the pick is - if that person seems to have the right credentials, then I'd get back in.
Again something as simple as getting Forfivo on track makes this a $2 stock IMO. If executing on Forfivo, they should have no problem generating $8-10M a year in royalties (that works out to less than 1/3 of the overall high dose bupropion market - a very realistic goal given they have no single dose competition). We'll see, certainly worth keeping an eye on.